Related Experiment Video
Updated: May 6, 2026
Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
Targeted quantitation of CVD-linked plasma proteins for biomarker verification and validation
Andrew J Percy1, Simon Byrns, Andrew G Chambers
1University of Victoria - Genome British Columbia Proteomics Centre, Vancouver Island Technology Park, #3101 - 4464 Markham St., Victoria, BC V8Z 7X8, Canada.
Insights
New methods for verifying cardiovascular disease (CVD) protein biomarkers in plasma are reviewed. These quantitative proteomic techniques aid in early detection and management of CVD, a leading global health issue.
Area of Science:
- Biochemistry
- Proteomics
- Cardiovascular Medicine
Background:
- Cardiovascular disease (CVD) is a major global cause of death and illness.
- Current risk factor monitoring is insufficient for controlling the CVD epidemic.
- Novel biomarkers are needed for improved CVD screening, detection, and management.
Purpose of the Study:
- To review quantitative proteomic methods for verifying and validating novel protein biomarker candidates in human plasma.
- To discuss strategies for enhancing CVD protein biomarker verification and validation.
- To provide recommendations for clinical translation and future research directions.
Main Methods:
- Focus on bottom-up quantitative proteomic approaches.
- Utilizes multiple or selected reaction monitoring for targeted peptide detection.
- Employs stable isotope-labeled standards for accurate peptide normalization.
Main Results:
- Quantitative proteomics offers robust methods for biomarker candidate verification.
- Targeted approaches with normalization are key for reliable validation.
- Few plasma protein biomarkers have been clinically validated to date.
Conclusions:
- Quantitative proteomic methods are essential for validating new CVD biomarkers.
- Standardized approaches are crucial for translating research findings to clinical practice.
- Further research and method development are needed to advance protein biomarker discovery for CVD.
Abstract:
Despite significant advances in treatment, cardiovascular disease (CVD) remains one of the leading causes of morbidity and mortality in developed and developing countries. Judicious monitoring of common risk factors has been unable to control this global epidemic, necessitating novel biomarkers for improved screening and earlier disease detection and management. Although numerous plasma proteins have been associated with CVD, only a few of these potential biomarkers have been validated for clinical use. Here we review the quantitative proteomic methods used to verify and validate new biomarker candidates in human plasma. These methods center on a bottom-up approach involving multiple or selected reaction monitoring, for targeted detection, with stable isotope-labeled standards, for peptide normalization. Also included are a discussion of future strategies for improved CVD protein biomarker verification and validation, recommendations for method translation to the clinic, and future projections for protein biomarker research.
